Evidence map›Paper›PMID 40518131›Full record

ArticleBritish journal of pharmacology2025

Defining the polycystin pharmacophore through high-throughput screening and computational biophysics.

Eduardo Guadarrama, Carlos G Vanoye, Paul G DeCaen

Abstract read
In one paragraph

Article in British journal of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Eduardo GuadarramaDepartment of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Carlos G VanoyeDepartment of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Paul G DeCaenDepartment of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0001-8776-983X

Funding

Molecular dysregulation of primary cilia TRPP2 channels caused by Finger 1 variantsR01DK123463 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI DECAEN, PAUL GREGORY · 2019 to 2023
$2.0M
Cilia calcium dysregulation in polycystic kidney diseaseR01DK131118 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Paul Gregory DeCaen · 2022 to 2026
$1.9M
SyncroPatch 384 Automated Patch Clamp InstrumentS10OD034362 · OD · NORTHWESTERN UNIVERSITY · PI GEORGE, ALFRED L. · 2023 to 2023
$599k
NIDDK NIH HHS R01 DK123463NIDDK NIH HHS R01 DK131118NIH HHS S10 OD034362PKDF
6 · The paper itself

Abstract

background and purposePolycystins (PKD2, PKD2L1) are voltage-gated and Ca EXPERIMENTAL APPROACH: HEK293 cells stably expressing PKD2L1 F514A were screened pharmacologically via high-throughput electrophysiology to identify potent polycystin channel modulators. In silico docking analysis and mutagenesis were used to define the receptor sites of screen hits. Inhibition by membrane-impermeable QX-314 was used to evaluate PKD2L1-binding site accessibility. KEY

resultsScreen results identify potent PKD2L1 inhibitors with divergent chemical core structures and highlight striking similarities between the molecular pharmacology of PKD2L1 and voltage-gated sodium channels. Docking analysis, channel mutagenesis and electrophysiological recordings identify an open-state accessible lateral fenestration receptor within the pore and a mechanism of inhibition that stabilises the PKD2L1 inactivated state. CONCLUSIONS AND IMPLICATIONS: Outcomes establish the suitability of our approach to expand our chemical knowledge of polycystins and delineate novel receptor moieties for the development of channel-specific inhibitors in TRP channel research.

Indexed as

Receptors, Cell SurfaceTRPP Cation ChannelsCalcium ChannelsHEK293 CellsHigh-Throughput Screening AssaysHumansMolecular Docking SimulationPharmacophoreCalcium ChannelsPKD2L1 protein, humanReceptors, Cell SurfaceTRPP Cation ChannelsADPKDautosomal polycystic kidney diseasecomputational biophysicshigh‐throughput electrophysiologyion channelsmolecular dockingmolecular mechanismspharmacologyPKD2L1. PKD2polycystinprimary ciliaTRP channels

Identifiers

PMID40518131
PMCPMC12862858

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.